Cargando…

Differential Mechanisms of Cell Death Induced by HDAC Inhibitor SAHA and MDM2 Inhibitor RG7388 in MCF-7 Cells

Gene expression is often altered by epigenetic modifications that can significantly influence the growth ability and progression of cancers. SAHA (Suberoylanilide hydroxamic acid, also known as Vorinostat), a well-known Histone deacetylase (HDAC) inhibitor, can stop cancer growth and metastatic proc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Natarajan, Umamaheswari, Venkatesan, Thiagarajan, Radhakrishnan, Vijayaraghavan, Samuel, Shila, Rathinavelu, Appu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356663/ https://www.ncbi.nlm.nih.gov/pubmed/30583560 http://dx.doi.org/10.3390/cells8010008

Ejemplares similares

Cell Cycle Arrest and Cytotoxic Effects of SAHA and RG7388 Mediated through p21(WAF1/CIP1) and p27(KIP1) in Cancer Cells
por: Natarajan, Umamaheswari, et al.
Publicado: (2019)

Effect of the HDAC Inhibitor on Histone Acetylation and Methyltransferases in A2780 Ovarian Cancer Cells
por: Natarajan, Umamaheswari, et al.
Publicado: (2021)

MDM2 Overexpression Modulates the Angiogenesis-Related Gene Expression Profile of Prostate Cancer Cells
por: Venkatesan, Thiagarajan, et al.
Publicado: (2018)

The MDM2 small-molecule inhibitor RG7388 leads to potent tumor inhibition in p53 wild-type neuroblastoma
por: Lakoma, A, et al.
Publicado: (2015)

Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer
por: Zanjirband, Maryam, et al.
Publicado: (2017)

Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma
por: Chen, Lindi, et al.
Publicado: (2015)

Phosphorus containing analogues of SAHA as inhibitors of HDACs
por: Pun, Michael D., et al.
Publicado: (2022)

MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388)
por: Khurana, Arushi, et al.
Publicado: (2019)

Prolonged Idasanutlin (RG7388) Treatment Leads to the Generation of p53-Mutated Cells
por: Skalniak, Lukasz, et al.
Publicado: (2018)

Comparison of Radiosensitization by HDAC Inhibitors CUDC-101 and SAHA in Pancreatic Cancer Cells
por: Moertl, Simone, et al.
Publicado: (2019)

Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer
por: Zanjirband, Maryam, et al.
Publicado: (2016)

The HDAC Inhibitor, SAHA, Combined with Cisplatin Synergistically Induces Apoptosis in Alpha-fetoprotein-producing Hepatoid Adenocarcinoma Cells
por: Kyaw, Myat Tin Htwe, et al.
Publicado: (2019)

HDAC inhibitors Tubastatin A and SAHA affect parasite cell division and are potential anti-Toxoplasma gondii chemotherapeutics
por: Araujo-Silva, Carlla Assis, et al.
Publicado: (2020)

In silico modification of suberoylanilide hydroxamic acid (SAHA) as potential inhibitor for class II histone deacetylase (HDAC)
por: Tambunan, Usman SF, et al.
Publicado: (2011)

The HDAC Inhibitor, SAHA, Prevents Colonic Inflammation by Suppressing Pro-inflammatory Cytokines and Chemokines in DSS-induced Colitis
por: Ali, Mohmand Noor, et al.
Publicado: (2018)

PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells
por: Yin, Linglong, et al.
Publicado: (2018)

Cardiomyogenic Differentiation Potential of Human Dilated Myocardium-Derived Mesenchymal Stem/Stromal Cells: The Impact of HDAC Inhibitor SAHA and Biomimetic Matrices
por: Miksiunas, Rokas, et al.
Publicado: (2021)

The HDAC inhibitor SAHA regulates CBX2 stability via a SUMO-triggered ubiquitin-mediated pathway in leukemia
por: Di Costanzo, Antonella, et al.
Publicado: (2018)

Correction to: PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/. BRCA1 DNA damage repair complex in prostate cancer cells
por: Yin, Linglong, et al.
Publicado: (2022)

A G-Quadruplex-Binding Small Molecule and the HDAC Inhibitor SAHA (Vorinostat) Act Synergistically in Gemcitabine-Sensitive and Resistant Pancreatic Cancer Cells †
por: Ahmed, Ahmed Abdullah, et al.
Publicado: (2020)

Synergistic antitumour activity of HDAC inhibitor SAHA and EGFR inhibitor gefitinib in head and neck cancer: a key role for ΔNp63α
por: Citro, Simona, et al.
Publicado: (2019)

Molecular Mechanism of SAHA on Regulation of Autophagic Cell Death in Tamoxifen-Resistant MCF-7 Breast Cancer Cells
por: Lee, Young Ju, et al.
Publicado: (2012)

Selection of an improved HDAC8 inhibitor through structure-based drug design
por: Vijayakumar, Balakrishnan, et al.
Publicado: (2011)

Antileukemic activity of combined epigenetic agents, DNMT inhibitors zebularine and RG108 with HDAC inhibitors, against promyelocytic leukemia HL-60 cells
por: Savickiene, Jurate, et al.
Publicado: (2012)

Upregulation of autophagy by Ginsenoside Rg2 in MCF-7 cells
por: Chung, Yuheon, et al.
Publicado: (2018)

Histone Deacetylase Inhibitor SAHA as Potential Targeted Therapy Agent for Larynx Cancer Cells
por: Grabarska, Aneta, et al.
Publicado: (2017)

The Bcl-2 inhibitor Obatoclax overcomes resistance to histone deacetylase inhibitors SAHA and LBH589 as radiosensitizers in patient-derived glioblastoma stem-like cells
por: Berghauser Pont, Lotte M.E., et al.
Publicado: (2014)

HGG-30. BRAIN PENETRANT HDAC INHIBITOR RG2833 SYNERGIZES WITH LOMUSTINE AND RADIATION TO INDUCE DIPG CELL DEATH
por: Barnett, Katherine, et al.
Publicado: (2021)

miR-16-5p enhances sensitivity to RG7388 through targeting PPM1D expression (WIP1) in Childhood Acute Lymphoblastic Leukemia
por: Zanjirband, Maryam, et al.
Publicado: (2023)

Histone Deacetylase (HDAC) Inhibitor, Suberoylanilide Hydroxamic Acid (SAHA), Induces Apoptosis in Prostate Cancer Cell Lines via the Akt/FOXO3a Signaling Pathway
por: Shi, Xuan-Yan, et al.
Publicado: (2017)

Development of a Bestatin-SAHA Hybrid with Dual Inhibitory Activity against APN and HDAC
por: Cao, Jiangying, et al.
Publicado: (2020)

DIPG-71. SELECTIVE HDAC INHIBITOR RG2833 INDUCES DIPG CELL DEATH VIA DOWNREGULATION OF THE NFĸB PATHWAY
por: Barnett, Katherine, et al.
Publicado: (2020)

Inhibition of HDAC3- and HDAC6-Promoted Survivin Expression Plays an Important Role in SAHA-Induced Autophagy and Viability Reduction in Breast Cancer Cells
por: Lee, Jane Ying-Chieh, et al.
Publicado: (2016)

Molecular dynamics simulation of complex Histones Deacetylase (HDAC) Class II Homo Sapiens with suberoylanilide hydroxamic acid (SAHA) and its derivatives as inhibitors of cervical cancer
por: Tambunan, Usman Sumo Friend, et al.
Publicado: (2013)

The histone deacetylase inhibitor SAHA acts in synergism with fenretinide and doxorubicin to control growth of rhabdoid tumor cells
por: Kerl, Kornelius, et al.
Publicado: (2013)

A novel regulation of VEGF expression by HIF-1α and STAT3 in HDM2 transfected prostate cancer cells
por: Rathinavelu, Appu, et al.
Publicado: (2012)

Oncogenic K-ras confers SAHA resistance by up-regulating HDAC6 and c-myc expression
por: Wang, Qun, et al.
Publicado: (2016)

Histone Deacetylase Inhibitor (SAHA) Reduces Mortality in an Endotoxemia Mouse Model by Suppressing Glycolysis
por: Wu, Yunchen, et al.
Publicado: (2023)

Dissection of Anti-tumor Activity of Histone Deacetylase Inhibitor SAHA in Nasopharyngeal Carcinoma Cells via Quantitative Phosphoproteomics
por: Huang, Huichao, et al.
Publicado: (2020)

Discovery of spirooxindole-derived small-molecule compounds as novel HDAC/MDM2 dual inhibitors and investigation of their anticancer activity
por: Zhao, Qian, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9h9mnahqv19t0neb3s8m8r6ro9